Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.

@article{Takashima2016TaxanesVS,
  title={Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.},
  author={Tsutomu Takashima and Hirofumi Mukai and Fumikata Hara and Nobuaki Matsubara and Tsuyoshi Saito and Toshimi Takano and Youngjin Park and Tatsuya Toyama and Yasuo Hozumi and Junji Tsurutani and Shigeru Imoto and Takanori Watanabe and Yoshiaki Sagara and Reiki Nishimura and Kojiro Shimozuma and Yasuo Ohashi},
  journal={The Lancet. Oncology},
  year={2016},
  volume={17 1},
  pages={90-8}
}
BACKGROUND Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting. METHODS We did an open-label, non-inferiority, phase 3 trial at 154 hospitals in Japan. We enrolled individuals who had HER2-negative metastatic breast cancer who had received no chemotherapy for advanced disease, and who were resistant to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 12 times over the past 90 days. VIEW TWEETS